

# Yazdan Yazdanpanah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2128985/publications.pdf>

Version: 2024-02-01

48  
papers

4,607  
citations

361045

20  
h-index

197535

49  
g-index

56  
all docs

56  
docs citations

56  
times ranked

10901  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. <i>Journal of Hepatology</i> , 2022, 76, 115-122.	1.8	6
2	Alpha (B.1.1.7) and Delta (B.1.617.2 "AY.40") SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage. <i>Journal of Infection</i> , 2022, 84, 418-467.	1.7	4
3	Screening and vaccination against COVID-19 to minimise school closure: a modelling study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 977-989.	4.6	37
4	Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. <i>Journal of Medical Virology</i> , 2021, 93, 2149-2159.	2.5	35
5	Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. <i>Clinical Microbiology and Infection</i> , 2021, 27, 789.e1-789.e5.	2.8	52
6	Nebulised interferon beta-1a for patients with COVID-19. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 122-123.	5.2	32
7	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial" authors" response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 277-279.	1.3	2
8	Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	181
9	Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19: A multicenter prospective cohort and literature review. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 1141-1158.	1.0	4
10	COVID-19 vaccines: A race against time. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100848.	0.6	11
11	High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. <i>Journal of Infection</i> , 2021, 82, 186-230.	1.7	7
12	Isoatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. <i>Lancet HIV</i> , the, 2021, 8, e324-e333.	2.1	24
13	Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1520.e1-1520.e5.	2.8	12
14	CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. <i>IScience</i> , 2021, 24, 102711.	1.9	79
15	Sociodemographic characteristics and transmission risk factors in patients hospitalized for COVID-19 before and during the lockdown in France. <i>BMC Infectious Diseases</i> , 2021, 21, 812.	1.3	4
16	Chronicles of a pandemic: How France coordinated the scientific research response to COVID-19. <i>Infectious Diseases Now</i> , 2021, 51, 641-646.	0.7	1
17	Partnership for Research on Ebola Vaccination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. <i>Trials</i> , 2021, 22, 86.	0.7	9
18	Temporal Trends in Suicide Attempts Among Children in the Decade Before and During the COVID-19 Pandemic in Paris, France. <i>JAMA Network Open</i> , 2021, 4, e2128611.	2.8	42

#	ARTICLE	IF	CITATIONS
19	Health status and healthcare trajectory of vulnerable asylum seekers hosted in a French Reception Center. <i>Travel Medicine and Infectious Disease</i> , 2021, , 102180.	1.5	3
20	COVID-19: France grapples with the pragmatics of isolation. <i>Lancet Public Health</i> , The, 2020, 5, e573-e574.	4.7	13
21	SARS-COV2 infection in 30 HIV-infected patients followed-up in a French University Hospital. <i>International Journal of Infectious Diseases</i> , 2020, 101, 49-51.	1.5	15
22	France's COVID-19 response: balancing conflicting public health traditions. <i>Lancet</i> , The, 2020, 396, 219-221.	6.3	20
23	Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia. <i>Cell Reports Medicine</i> , 2020, 1, 100059.	3.3	188
24	A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	228
25	Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2404-2413.	1.1	6
26	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2376-2380.	1.3	25
27	Clinical and virological data of the first cases of COVID-19 in Europe: a case series. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 697-706.	4.6	953
28	Case report study of the first five COVID-19 patients treated with remdesivir in France. <i>International Journal of Infectious Diseases</i> , 2020, 98, 290-293.	1.5	30
29	Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study. <i>Lancet</i> , The, 2020, 395, 871-877.	6.3	931
30	Type 1 interferons as a potential treatment against COVID-19. <i>Antiviral Research</i> , 2020, 178, 104791.	1.9	425
31	HIV Infection in North African Patients. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 628-633.	0.5	1
32	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i> ,the, 2019, 6, e355-e363.	2.1	107
33	Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1992-2002.	1.3	8
34	HepCare Europe: a new user-friendly hepatitis C care service model. What have we learned? What are the remaining challenges?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, v2-v4.	1.3	0
35	Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 473-481.	0.8	6
36	Prevention of Ebola virus disease through vaccination: where we are in 2018. <i>Lancet</i> , The, 2018, 392, 787-790.	6.3	103

#	ARTICLE	IF	CITATIONS
37	Vaccination and blood sampling acceptability during Ramadan fasting month: A cross-sectional study in Conakry, Guinea. <i>Vaccine</i> , 2017, 35, 2569-2574.	1.7	10
38	Evidence of Sexual Transmission of Zika Virus. <i>New England Journal of Medicine</i> , 2016, 374, 2195-2198.	13.9	632
39	Long-Lasting Persistence of Zika Virus in Semen. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw509.	2.9	57
40	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease". <i>Journal of Hepatology</i> , 2016, 65, 1065-1066.	1.8	1
41	Zika virus infection: report of the first imported cases in a Paris travel centre: Table 1. <i>Journal of Travel Medicine</i> , 2016, 24, taw066.	1.4	14
42	Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2016, 65, 40-47.	1.8	161
43	A Case of <i>Aggregatibacter aphrophilus</i> Multiple Abscess. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv031.	0.4	6
44	Sternal Wound Infection after Cardiac Surgery: Management and Outcome. <i>PLoS ONE</i> , 2015, 10, e0139122.	1.1	21
45	Predictors of return rate for an HIV-positive result in a French Voluntary Counseling and Testing centre. <i>International Journal of STD and AIDS</i> , 2015, 26, 33-36.	0.5	7
46	Drug assessment in the Ebola virus disease epidemic in west Africa. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1258.	4.6	8
47	HIV-serodiscordant couples desiring a child: "treatment as prevention," preexposure prophylaxis, or medically assisted procreation?. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 341.e1-341.e12.	0.7	13
48	Trends in Condom Use and Risk Behaviours after Sexual Exposure to HIV: A Seven-Year Observational Study. <i>PLoS ONE</i> , 2014, 9, e104350.	1.1	13